Preclinical data for drug registration in South Korea must comply with guidelines set by the Ministry of Food and Drug Safety (MFDS). This includes safety and efficacy data from laboratory and animal studies, conducted under Good Laboratory Practice (GLP) standards. The data should demonstrate toxicity, pharmacokinetics, and pharmacodynamics to support clinical trial approval.
